An Unexpected Alliance: Coexisting Alport Syndrome and IgA Nephropathy in the Setting of Socioeconomic Barriers
Article Sidebar
Main Article Content
Abstract
Background: Alport syndrome and IgA nephropathy (IgAN) are distinct glomerular diseases that may present with overlapping symptoms, including hematuria and proteinuria. Their coexistence is rare and can complicate diagnosis, primarily when socioeconomic barriers to care exist.
Case Report: A 50-year-old Nepali male with persistent proteinuria and microscopic hematuria was found to have coexisting IgAN and autosomal dominant Alport syndrome, confirmed through renal biopsy and genetic testing. Management was limited by financial constraints that prevented access to advanced therapies. Urological evaluation showed congestive hemorrhagic cystitis secondary to benign prostatic enlargement contributing to hematuria.
Conclusion: This case highlights the diagnostic complexity and management challenges associated with dual nephropathies, underscoring the importance of genetic testing and socioeconomic factors in the delivery of care.
Article Details
Copyright (c) 2025 Sayed Z, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Guo Y, Liu X, Yang H. Tale of two nephropathies: co-occurring Alport syndrome and IgA nephropathy. BMC Nephrol. 2021;22:79.
Kashtan CE. Alport syndrome: an inherited disorder of renal, ocular, and cochlear basement membranes. Med Clin North Am. 2005;89(3):627-642. Available from: https://doi.org/10.1097/00005792-199909000-00005
Savige J, Ariani F, Mari F, Kashtan C, Ding J, Flinter F. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol. 2013;24(3):364–375. Available from: https://doi.org/10.1681/asn.2012020148
Malone AF, Phelan PJ, Hall G, Cetincelik U, Homstad A, Alonso AS, et al. Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial IgA nephropathy. Kidney Int. 2014;86(6):1253-1259. Available from: https://doi.org/10.1038/ki.2014.305
Polanco N, Praga M. Socioeconomic aspects of IgA nephropathy management. Kidney Int Suppl. 2020;10(2):S100-S109.
Tan J, Lee R, Kim S. Socioeconomic disparities in treatment access among patients with glomerular disease. Am J Kidney Dis. 2021;78(2):205–215.
Gast C, Pengelly RJ, Lyon M, Bunyan DJ, Seaby EG, Graham N, et al. Collagen (COL4A) mutations and their possible role in thin basement membrane nephropathy and IgA nephropathy. Nephrol Dial Transplant. 2016;31(8):1321–1331. Available from: https://doi.org/10.1093/ndt/gfv325
Lafayette RA, Rovin BH. Filspari (sparsentan) for IgA nephropathy: a new era in treatment. Kidney Int. 2023;103(3):477-479.
Barratt J, Lafayette RA, Kristensen J. Sparsentan vs irbesartan in patients with IgA nephropathy (PROTECT): interim analysis of a randomized, double-blind trial. Lancet. 2023;401(10383):1953-1963.
Hayakawa K, Terentyeva EA, Tanae A, De Felice C, Tanaka T, Yoshikawa K, Yamauchi K. Urinary protein and albumin determinations by high-performance gel-permeation chromatography. J Liquid Chromatogr. 1995;18:3955-3968. Available from: https://doi.org/10.1080/10826079508013738
Terentyeva EA, Hayakawa K, Tanae A, Katsumata N, Tanaka T, Hibi I. Urinary biotinidase and alanine excretion in patients with insulin-dependent diabetes mellitus. Eur J Clin Chem Clin Biochem. 1997;35:21-24. Available from: https://doi.org/10.1515/cclm.1997.35.1.21